2 terminated, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow trebananib: new trials by email Literature Review of trebananib trials Research Report on trebananib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer AMG 386, Paclitaxel, AMG 386 Placebo - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 1015 | 2012-01-01 | 2017-02-23 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) AMG386 plus PLD, Placebo plus PLD - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 223 | 2011-04-18 | 2017-12-02 |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer AMG 386, AMG 386 Placebo, Paclitaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Completed | Amgen | 919 | 2010-11-01 | 2016-12-15 |
Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Ovarian Epithelial (1)
Amgen (3)
Belgium (3) · Canada (3) · Hong Kong (3) · Italy (3) · United States (3) · Australia (2) · Austria (2) · Denmark (2) · France (2) · Germany (2) · Greece (2) · Japan (2) · Poland (2) · Russia (2) · South Korea (2)
PMID 37185961, PMID 27029706, PMID 31076365, PMID 37407274
2009 (1)